July 2019 Midatech Pharma PLC ("Midatech" or the "Company") Appointment of Non-Executive Director Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D biotechnology company focused on delivering innovative oncology an

("Midatech" or the "Company")

Appointment of Non-Executive Director

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:

MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased

to announce the appointment of Fr d ric Duchesne, former President and Chief Executive Officer of the Pharmaceuticals

Division of Pierre Fabre Laboratories, to the Board of the Company as a Non-Executive Director with immediate effect. Mr Duchesne

brings more than three decades of experience and leadership in commercial, strategic planning, product development, business development,

market access, supply chain and manufacturing roles in major pharmaceutical companies.

During his tenure at Pierre Fabre from

2010 until May 2019, Mr. Duchesne was in charge of transforming the Pharmaceuticals Division into a robust 1 billion OTX

and Specialty Care business and led Pierre Fabre to become a commercial partner of choice in Europe for Biotech and mid-size Pharma

Mr Duchesne has previously also held senior

positions with Sanofi working in their manufacturing operations, SmithKline Beecham as Director of Production and Logistics, Glaxo

SmithKline as Vice-President and Director of Commercial Operations, then moving to Bristol-Myers Squibb as Vice President and Director

of Commercial Operations, and subsequently Vice President Europe and Managing Director of Bristol-Myers Squibb UK

Rolf Stahel, Midatech's Chairman

commented: "Fr d ric brings a wealth of key experience and credentials at the highest level from his successful

pharmaceutical career. I am very pleased to welcome such an exceptional individual to further strengthen our Board's breadth

of talent and depth of knowledge. I look forward to working with Fr d ric and am very confident he will make an important

and positive impact to Midatech across the business, particularly with the next, important stage in developing our manufacturing

capabilities and commercialising the Company's assets, as the Company continues to develop its key projects through their

clinical phase and towards their successful launch."

Fr d ric Duchesne commented:

"I am delighted to join the Midatech Board and very much look forward to contributing to the success of the Company in any

way I can. I am impressed by Midatech's innovative programmes and drug delivery technologies, the recent progress and clear

potential of the Company for the future. The Company's focus on making a difference for patients suffering from rare oncology

diseases is an exciting and stimulating opportunity that was also a key factor in my decision to join the Board. I'm honoured

to be joining the Board and I look forward to working with the management team."

a doctorate in Industrial Pharmacy, a diploma from the Institute of Industrial Pharmacy and a diploma in Health Care Law from Paris-Sud

Rule 17 and Schedule Two paragraph (g)

of the AIM Rules for Companies

The following information is disclosed pursuant to Rule 17 and

Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Fr d ric Duchesne, aged 60:

As of the date of this announcement, Fr d ric

Duchesne holds no ordinary shares in the capital of the Company.

Save as disclosed above there are no additional

disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For more information, please contact:

(UK) Limited (Nominated Adviser and Broker)

Emma Earl (Corporate Finance)

Limited (Financial PR and UK Investor Relations)

Graham Herring / Heather Armstrong

Email: midatech@investor-focus.co.uk

Westwicke Partners (US Investor Relations)

Tel: +1 339 970 2843

Email: chris.brinzey@westwicke.com

Midatech Pharma PLC (dual listed on LSE

AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving delivery of drugs

in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to

provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing

treatment for life threatening diseases.

The Company has developed three in-house

technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's

technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

By improving biodelivery and biodistribution

of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks,

accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies

allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility

is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com

in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom

and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech

to successfully test, manufacture, produce or commercialize products for conditions using its technology platforms, and the ability

for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with

pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available

competitive, financial and economic data together with management's views and assumptions regarding future events and business

performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there

are some known and unknown factors that could cause actual results to differ materially from any future results, performance or

achievements expressed or implied by such forward-looking statements.

be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance

with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs")

and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important

factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements.

These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking

statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may

be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake

any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise